Jaw-Wen Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jaw-Wen Chen has a total of 340 co-authors. Here are the top co-authors by number of shared publications:
Shing-Jong Lin
Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
33 shared publications- Shing-Jong Lin
Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
29 shared publications Tao-Cheng Wu
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
25 shared publicationsHsin-Bang Leu
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
24 shared publicationsPo-Hsun Huang
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
20 shared publications- Hsin-Bang Leu
Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou Dist., Taipei City, Taiwan
19 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (5) , 791-800
Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study
Aims/Introduction: Diabetes mellitus significantly contributes to renal complications, especially in patients with coronary artery disease (CAD). Effective glycemic control is important; however, the ideal hemoglobin A1c (HbA1c) targets for this population remain uncertain. This observational cohort study aimed to identify appropriate HbA1c targets for patients with diabetes and chronic coronary syndrome. Materials and Methods: This study included 1,223 patients with chronic coronary syndrome, which were identified from a multicenter cohort registry study. Among them, there were 698 patients with diabetes. Patients were categorized based on their diabetes status and HbA1c levels. The primary outcome was the incidence of minor and major renal events, defined as a decline in the estimated glomerular filtration rate (eGFR) of more than 25% and 50%. Cox proportional hazards regression models were employed to assess the impact of glycemic control on renal function. Results: Over a mean follow‐up of 3.2 ± 2.0 years, the highest incidences of minor renal events were noted in the group with diabetes and HbA1c ≥ 7.5% (25.1%), followed by diabetes and HbA1c < 6.5% (21.2%). Compared to the group without diabetes, the adjusted hazard ratios (95% confidence intervals) for minor renal events in the groups with diabetes and HbA1c ≥ 7.5%, HbA1c 7.0–7.4%, HbA1c 6.5–6.9%, and HbA1c < 6.5% were 3.06 (2.08–4.50), 1.75 (1.08–2.84), 1.32 (0.81–2.23), and 2.59 (1.58–4.24), respectively. Conclusions: Achieving HbA1c of 6.5 to 6.9% is associated with a reduced risk of renal complications in patients with diabetes and chronic coronary syndrome.
- 27 February 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (5) , 791-800
Open AccessGlycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study
Aims/Introduction: Diabetes mellitus significantly contributes to renal complications, especially in patients with coronary artery disease (CAD). Effective glycemic control is important; however, the ideal hemoglobin A1c (HbA1c) targets for this population remain uncertain. This observational cohort study aimed to identify appropriate HbA1c targets for patients with diabetes and chronic coronary syndrome. Materials and Methods: This study included 1,223 patients with chronic coronary syndrome, which were identified from a multicenter cohort registry study. Among them, there were 698 patients with diabetes. Patients were categorized based on their diabetes status and HbA1c levels. The primary outcome was the incidence of minor and major renal events, defined as a decline in the estimated glomerular filtration rate (eGFR) of more than 25% and 50%. Cox proportional hazards regression models were employed to assess the impact of glycemic control on renal function. Results: Over a mean follow‐up of 3.2 ± 2.0 years, the highest incidences of minor renal events were noted in the group with diabetes and HbA1c ≥ 7.5% (25.1%), followed by diabetes and HbA1c < 6.5% (21.2%). Compared to the group without diabetes, the adjusted hazard ratios (95% confidence intervals) for minor renal events in the groups with diabetes and HbA1c ≥ 7.5%, HbA1c 7.0–7.4%, HbA1c 6.5–6.9%, and HbA1c < 6.5% were 3.06 (2.08–4.50), 1.75 (1.08–2.84), 1.32 (0.81–2.23), and 2.59 (1.58–4.24), respectively. Conclusions: Achieving HbA1c of 6.5 to 6.9% is associated with a reduced risk of renal complications in patients with diabetes and chronic coronary syndrome.
- 8 December 2025
- Published by Elsevier in Life Sciences
- Vol. 385, 124143
Sodium nitroprusside improves ischemia-induced neovascularization via the HO-1/NOX and AKT/eNOS signaling pathways in chronic kidney disease
- 8 December 2025
- Published by Elsevier in Life Sciences
- Vol. 385, 124143
Sodium nitroprusside improves ischemia-induced neovascularization via the HO-1/NOX and AKT/eNOS signaling pathways in chronic kidney disease
- Open Access
- 28 February 2025
- Published by Springer Nature in Angiogenesis
- Vol. 28 (2) , 1-15
Correction: CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation
- 28 February 2025
- Published by Springer Nature in Angiogenesis
- Vol. 28 (2) , 1-15
Open AccessCorrection: CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation
- Open Access
- 7 February 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-13
Prognostic utility of neutrophil gelatinase-associated lipocalin (NGAL) levels for cardiovascular events in patients with stable coronary artery disease treated with percutaneous coronary intervention: a prospective longitudinal cohort study
Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) modulates the enzymatic activity of matrix metalloproteinase-9, which is an important mediator of plaque instability in atherosclerosis. High NGAL levels can independently predict all-cause mortality and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI). However, studies that have measured NGAL levels in patients with stable coronary artery disease (CAD) are limited. Furthermore, no significant prognostic predictive value between NGAL levels and stable CAD has been established. Hypothesis: We aimed to investigate the prognostic role of NGAL levels in a prospective cohort study of patients with stable CAD treated with percutaneous coronary intervention (PCI). Methods: A total of 2,238 stable patients with CAD and a previous PCI were enrolled in a multicenter prospective observational study (The National Taiwan Biosignature Research, NTBR) in Taiwan. The primary outcome was the occurrence of MACE (cardiovascular death, nonfatal myocardial infarction, and ischemic stroke). The secondary outcome was a composite of cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, and hospitalization for heart failure). Results: During the mean follow-up period of 4.6 ± 1.7 years, 441 patients reached the primary endpoints. Kaplan-Meier analysis showed that event-free survival was significantly different between the first and third tertile groups (log-rank test, p < 0.001) in subjects categorized by NGAL levels. In a multivariate Cox proportional hazard regression analysis, plasma NGAL levels were independently associated with an increased risk of MACE [adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (CI) = 1.18–1.54, p < 0.001], AMI (aHR = 1.34; 95% CI = 1.12–1.59, p < 0.001), and target vessel revascularization (aHR = 1.35; 95% CI = 1.19–1.53, p < 0.001). Addition of serum NGAL levels to the traditional risk model improved its prediction value for future cardiovascular events. Conclusions: High plasma NGAL levels were independently associated with the occurrence of MACE and composite cardiovascular events in patients with stable PCI-treat CAD.
- 7 February 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-13
Open AccessPrognostic utility of neutrophil gelatinase-associated lipocalin (NGAL) levels for cardiovascular events in patients with stable coronary artery disease treated with percutaneous coronary intervention: a prospective longitudinal cohort study
Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) modulates the enzymatic activity of matrix metalloproteinase-9, which is an important mediator of plaque instability in atherosclerosis. High NGAL levels can independently predict all-cause mortality and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI). However, studies that have measured NGAL levels in patients with stable coronary artery disease (CAD) are limited. Furthermore, no significant prognostic predictive value between NGAL levels and stable CAD has been established. Hypothesis: We aimed to investigate the prognostic role of NGAL levels in a prospective cohort study of patients with stable CAD treated with percutaneous coronary intervention (PCI). Methods: A total of 2,238 stable patients with CAD and a previous PCI were enrolled in a multicenter prospective observational study (The National Taiwan Biosignature Research, NTBR) in Taiwan. The primary outcome was the occurrence of MACE (cardiovascular death, nonfatal myocardial infarction, and ischemic stroke). The secondary outcome was a composite of cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, and hospitalization for heart failure). Results: During the mean follow-up period of 4.6 ± 1.7 years, 441 patients reached the primary endpoints. Kaplan-Meier analysis showed that event-free survival was significantly different between the first and third tertile groups (log-rank test, p < 0.001) in subjects categorized by NGAL levels. In a multivariate Cox proportional hazard regression analysis, plasma NGAL levels were independently associated with an increased risk of MACE [adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (CI) = 1.18–1.54, p < 0.001], AMI (aHR = 1.34; 95% CI = 1.12–1.59, p < 0.001), and target vessel revascularization (aHR = 1.35; 95% CI = 1.19–1.53, p < 0.001). Addition of serum NGAL levels to the traditional risk model improved its prediction value for future cardiovascular events. Conclusions: High plasma NGAL levels were independently associated with the occurrence of MACE and composite cardiovascular events in patients with stable PCI-treat CAD.
- Open Access
- 10 January 2025
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 88 (4) , 267-272
Potential beneficial impacts of tadalafil on cardiovascular diseases
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy. Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.
- 10 January 2025
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 88 (4) , 267-272
Open AccessPotential beneficial impacts of tadalafil on cardiovascular diseases
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy. Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.
- 9 September 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (4) , 939-953
Inhibition of Adipocyte-Derived FABP4 Reduces Adipocyte Inflammation, Improves Angiogenesis, and Facilitates Wound Healing in Metabolic Dysfunctions
- 9 September 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (4) , 939-953
Inhibition of Adipocyte-Derived FABP4 Reduces Adipocyte Inflammation, Improves Angiogenesis, and Facilitates Wound Healing in Metabolic Dysfunctions
- 4 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (763) , eadn1507
Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus
Diabetic vascular disease is a major complication of diabetes mellitus (DM). Chemokine C-C motif ligand 7 (CCL7) attracts macrophages and monocytes, amplifying inflammatory processes in the vasculature. We hypothesized a causal role for CCL7 in diabetic vasculopathy. CCL7 concentrations were higher in the plasma of patients with type 2 DM, as well as in supernatants from their endothelial progenitor cells (EPCs). High-glucose stimulation increased the secretion of CCL7 from human dermal microvascular endothelial cells (HDMECs) through the c-Fos and c-Jun signaling pathways. CCL7 inhibition using knockdown or neutralization antibody treatment reversed the high glucose–induced impaired tube formation and migration abilities of EPCs, human aortic endothelial cells, human coronary artery endothelial cells, and HDMECs. Administration of recombinant human CCL7 protein impaired tube formation and migration abilities by down-regulating the AKT–endothelial nitric oxide synthase and AKT/nuclear factor erythroid 2–related factor 2/heme oxygenase–1/vascular endothelial growth factor/stromal cell–derived factor–1 pathways and by up-regulating ERK/phosphorylated p65/interleukin-1β/interleukin-6/tumor necrosis factor–α pathways through CC chemokine receptor 3 in endothelial cells. Ccl7 knockout in streptozotocin-treated mice showed improved neovasculogenesis in ischemic limbs and accelerated wound repair, with increased circulating EPCs and capillary density. CCL7 antibody treatment in db/db mice and high-fat diet–induced hyperglycemia mice showed improved neovasculogenesis in ischemic limbs and wound areas, accompanied by up-regulation of angiogenic proteins and down-regulation of inflammatory proteins. Endothelial cell–specific Ccl7 -knockout mice showed ameliorated diabetic vasculopathy in streptozotocin-induced DM. This study highlights the potential of CCL7 as a therapeutic target for diabetic vasculopathy.
- 4 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (763) , eadn1507
Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus
Diabetic vascular disease is a major complication of diabetes mellitus (DM). Chemokine C-C motif ligand 7 (CCL7) attracts macrophages and monocytes, amplifying inflammatory processes in the vasculature. We hypothesized a causal role for CCL7 in diabetic vasculopathy. CCL7 concentrations were higher in the plasma of patients with type 2 DM, as well as in supernatants from their endothelial progenitor cells (EPCs). High-glucose stimulation increased the secretion of CCL7 from human dermal microvascular endothelial cells (HDMECs) through the c-Fos and c-Jun signaling pathways. CCL7 inhibition using knockdown or neutralization antibody treatment reversed the high glucose–induced impaired tube formation and migration abilities of EPCs, human aortic endothelial cells, human coronary artery endothelial cells, and HDMECs. Administration of recombinant human CCL7 protein impaired tube formation and migration abilities by down-regulating the AKT–endothelial nitric oxide synthase and AKT/nuclear factor erythroid 2–related factor 2/heme oxygenase–1/vascular endothelial growth factor/stromal cell–derived factor–1 pathways and by up-regulating ERK/phosphorylated p65/interleukin-1β/interleukin-6/tumor necrosis factor–α pathways through CC chemokine receptor 3 in endothelial cells. Ccl7 knockout in streptozotocin-treated mice showed improved neovasculogenesis in ischemic limbs and accelerated wound repair, with increased circulating EPCs and capillary density. CCL7 antibody treatment in db/db mice and high-fat diet–induced hyperglycemia mice showed improved neovasculogenesis in ischemic limbs and wound areas, accompanied by up-regulation of angiogenic proteins and down-regulation of inflammatory proteins. Endothelial cell–specific Ccl7 -knockout mice showed ameliorated diabetic vasculopathy in streptozotocin-induced DM. This study highlights the potential of CCL7 as a therapeutic target for diabetic vasculopathy.
- Open Access
- 13 May 2024
- Published by Springer Nature in Angiogenesis
- Vol. 27 (3) , 475-499
CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation
Aging is a natural process associated with chronic inflammation in the development of vascular dysfunction. We hypothesized that chemokine C-C motif ligands 4 (CCL4) might play a vital role in aging-related vascular dysfunction. Circulating CCL4 was up-regulated in elderly subjects and in aged animals. CCL4 inhibition reduced generation of reactive oxygen species (ROS), attenuated inflammation, and restored cell functions in endothelial progenitor cells from elderly subjects and in aged human aortic endothelial cells. CCL4 promoted cell aging, with impaired cell functioning, by activating ROS production and inflammation. CCL4 knockout mice and therapeutic administration of anti-CCL4 neutralizing antibodies exhibited vascular and dermal anti-aging effects, with improved wound healing, via the down-regulation of inflammatory proteins and the activation of angiogenic proteins. Altogether, our findings suggested that CCL4 may contribute to aging-related vascular dysfunction via activating oxidative stress and endothelial inflammation. CCL4 may be a potential therapeutic target for vascular protections during aging.
- 13 May 2024
- Published by Springer Nature in Angiogenesis
- Vol. 27 (3) , 475-499
Open AccessCCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation
Aging is a natural process associated with chronic inflammation in the development of vascular dysfunction. We hypothesized that chemokine C-C motif ligands 4 (CCL4) might play a vital role in aging-related vascular dysfunction. Circulating CCL4 was up-regulated in elderly subjects and in aged animals. CCL4 inhibition reduced generation of reactive oxygen species (ROS), attenuated inflammation, and restored cell functions in endothelial progenitor cells from elderly subjects and in aged human aortic endothelial cells. CCL4 promoted cell aging, with impaired cell functioning, by activating ROS production and inflammation. CCL4 knockout mice and therapeutic administration of anti-CCL4 neutralizing antibodies exhibited vascular and dermal anti-aging effects, with improved wound healing, via the down-regulation of inflammatory proteins and the activation of angiogenic proteins. Altogether, our findings suggested that CCL4 may contribute to aging-related vascular dysfunction via activating oxidative stress and endothelial inflammation. CCL4 may be a potential therapeutic target for vascular protections during aging.
- Open Access
- 13 May 2024
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (8) , 952-968
Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease
Background: Both the clinical and mechanistic impacts of endocan were not well elucidated especially in coronary artery disease (CAD). Objective: This study aimed to investigate the prognostic and potential pathological role of endocan for cardiovascular (CV) events in stable CAD patients. Methods: A total of 1,071 stable CAD patients with previous percutaneous coronary intervention (PCI) were enrolled prospectively in a nationwide Biosignature study. Another cohort of 76 CAD patients with or without PCI were enrolled for validation. Baseline biomarkers including endocan level was measured and total CV events especially hard CV events (including CV mortality, non-fatal myocardial infection and stroke) during follow-up were identified. Circulating endothelial progenitor cells (EPCs) as an in vivo biological contributor to vascular repairment from CAD patients were used for the in vitro functional study. Results: After 24 months, there were 42 patients (3.92%) with hard CV events and 207 (19.3%) with total CV events in the study group. The incidence of both events was increased with the tertiles of baseline endocan level (hard events: 1.7%,3.4%, and 6.7% in 1st,2nd, and 3rd tertile respectively, p = 0.002; total events: 13.8%vs.16.2%vs.28.0%, p < 0.0001). Multivariate regression analysis revealed the independent association of endocan level with total and hard CV events. These findings were validated in another cohort with a 5-year follow-up. Furthermore, in vitro inhibition of endocan improved cell migration and tube formation capacities, and reduced cell adhesiveness of EPCs from CAD patients. Conclusions: Endocan might be a novel prognostic indicator, mechanistic mediator, and potential therapeutic target for clinical CAD. Graphical
- 13 May 2024
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (8) , 952-968
Open AccessNovel prognostic impact and cell specific role of endocan in patients with coronary artery disease
Background: Both the clinical and mechanistic impacts of endocan were not well elucidated especially in coronary artery disease (CAD). Objective: This study aimed to investigate the prognostic and potential pathological role of endocan for cardiovascular (CV) events in stable CAD patients. Methods: A total of 1,071 stable CAD patients with previous percutaneous coronary intervention (PCI) were enrolled prospectively in a nationwide Biosignature study. Another cohort of 76 CAD patients with or without PCI were enrolled for validation. Baseline biomarkers including endocan level was measured and total CV events especially hard CV events (including CV mortality, non-fatal myocardial infection and stroke) during follow-up were identified. Circulating endothelial progenitor cells (EPCs) as an in vivo biological contributor to vascular repairment from CAD patients were used for the in vitro functional study. Results: After 24 months, there were 42 patients (3.92%) with hard CV events and 207 (19.3%) with total CV events in the study group. The incidence of both events was increased with the tertiles of baseline endocan level (hard events: 1.7%,3.4%, and 6.7% in 1st,2nd, and 3rd tertile respectively, p = 0.002; total events: 13.8%vs.16.2%vs.28.0%, p < 0.0001). Multivariate regression analysis revealed the independent association of endocan level with total and hard CV events. These findings were validated in another cohort with a 5-year follow-up. Furthermore, in vitro inhibition of endocan improved cell migration and tube formation capacities, and reduced cell adhesiveness of EPCs from CAD patients. Conclusions: Endocan might be a novel prognostic indicator, mechanistic mediator, and potential therapeutic target for clinical CAD. Graphical
- 9 August 2023
- Published by Elsevier in Life Sciences
- Vol. 330, 122018
Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease
- 9 August 2023
- Published by Elsevier in Life Sciences
- Vol. 330, 122018
Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease